Publications by authors named "C Kasavanesi Ramakrishna"

Article Synopsis
  • Membranoproliferative glomerulonephritis (MPGN) is a kidney condition identified through biopsy, with various causes, and this study explores data from a UK renal center over 20 years.* -
  • The study involved 38 identified patients, primarily older (median age 61), with a significant percentage suffering from immune complex-mediated MPGN, and highlighted treatment approaches and clinical outcomes.* -
  • Findings indicated that nearly 50% of patients progressed to end-stage kidney disease (ESKD) or died, suggesting the need for personalized patient management and further research to improve understanding and outcomes.*
View Article and Find Full Text PDF
Article Synopsis
  • Tyk2, part of the JAK kinase family, plays a key role in inflammation and is linked to autoimmune disorders.
  • Targeting Tyk2 selectively could lead to fewer side effects than traditional JAK inhibitors, prompting increased research into its therapeutic potential.
  • The drug Deucravacitinib is now approved for psoriasis, and other Tyk2 inhibitors are being studied for various autoimmune diseases like psoriatic arthritis and inflammatory bowel disease.
View Article and Find Full Text PDF

Systematic genome-wide analysis of revealed the identification of a total of 48 homologous genes comprising 21 proline-rich proteins () and 27 hybrid proline-rich proteins (). Comprehensive scrutiny of these gene homologs was conducted for gene structure, phylogenetic investigations, chromosome mapping, and subcellular localization of proteins. Promoter analysis uncovered the regions rich with phosphorous- (BIHD), ammonium-, sulfur-responsive (SURE), and iron starvation-responsive (IRO2) along with biotic, abiotic, and development-specific -elements.

View Article and Find Full Text PDF

Background: A picture archiving and communication system (PACS) is a means wherein the images are acquired, displayed, transmitted, and stored digitally. Bone Ninja is an application on iPad (Apple Inc.) on the IOS platform, developed as a teaching tool for deformity corrections around the knee.

View Article and Find Full Text PDF

Background: Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency.

Methods: In total, 588 patients with a clinical diagnosis of anemia due to CKD without dialysis need and with baseline hemoglobin of 7.0-10.

View Article and Find Full Text PDF